Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| I think for -- you didn't ask for Cenerimod really, but I think Cenerimod in terms of differentiation, clearly, we've seen a very strong Phase 2 data that supports a differentiated and highly-competitive benefit risk profile |
| We have an extraordinarily strong base and global reach from a commercial perspective in this company |
| Sanjeev has helped the company to successfully execute our Phase 1 strategy since 2020 |
| We continue to generate strong free cash flows |
| With our ability, beginning in 2024, to use our substantial free cash flow to both return capital to shareholders and to make strategic investments to grow our business, we are truly evolving into the strong and unique company that we have envisioned |
| This was the third consecutive quarter of operational revenue growth, and we continue to see solid performance across Developed Markets, Emerging Markets in our Greater China segment |
| Certainly, we've got a very solid base business that we see growing at a couple of percent a year as we move forward |
| On a full year basis, adjusted gross margin came in at the high end of our expectation at 59.1%, driven by strong brand performance |
| We believe that together, we will be able to execute on the potential of these global assets and any future assets, as we work to deliver on our goal of building a more durable, predictable portfolio on the foundation of our strong base business |
| Our results were in line or better than our expectations |
| We finished the year strong with full year results in line operationally with our 2023 adjusted guidance |
| Importantly, our fourth quarter results represent our third consecutive quarter of operational revenue growth, giving us good momentum going into the new year |
| 2023 was another strong year across total revenue, adjusted EBITDA and free cash flow |
| And just one comment is, I think the solid base of the company that we built through ‘21, ‘22, ‘23 and into ‘24 really provides us that opportunity to look for appropriate business development opportunities to build off that base and grow in the future |
| I'm very pleased with where we are today in Viatris' journey, and the strength as well as stability of our core business, which is now nicely set up for continued growth from here onwards |
| The agreement combines Viatris' financial strength and worldwide operational infrastructure, with a portfolio of novel assets that we believe will provide the foundation for accelerated top line growth |
| So I believe this is going to be good for overall the health of the industry, the generics industry |
| This collaboration has the potential to enhance our growth profile by delivering a strong portfolio of branded, patent-protected assets targeting significant unmet patient needs, while leveraging our capabilities in therapeutic areas where we have differentiated insights |
| We had another strong year of free cash flow generation, reflecting our underlying operational performance and continued priority on cash optimization initiatives |
| The strong free cash flow generation over the last three years exceeded $7.5 billion, and has enabled us to deliver on our financial commitment |
| Greater China performed ahead of our expectations for the full-year 2023, delivering 2% growth, driven by strong performance of our retail channel in China |
| And revenue as these prescriptions pick up, we'll obviously -- each quarter is going to be better than previous quarter for modeling purposes |
| I'm pleased to have Doretta coming on board for what I expect to be an extremely successful next phase of Viatris |
| These positive actions taken by the company reinforce our continuing commitment to an investment-grade rating and an expectation of increasing the return of capital to our shareholders |
| These better-than-expected results benefited from strength across our broader generics portfolio and stronger-than-expected performance from brands like Dymista and Viagra, led by markets such as Turkey, South Korea and Southeast Asia |
| As we close Phase 1 of our strategy, I'm incredibly proud of all that we have accomplished |
| So all the indications are very solid, and we are seeing that expansion of the excess |
| We continue to deliver on our strong pipeline and are in the final stages of reshaping the company with remaining divestitures being on track |
| We believe that the stability of our core business and our deep pipeline positions the company very well for continued growth into '24 and beyond |
| Emerging Markets had another strong year, delivering 7% year-over-year operational growth in '23 |
| Statement |
|---|
| Full-year '23 came in below our expectations due to the continued impacts from the government-driven price regulations in this region, which we expect to continue into 2024 |
| And that kind of drives that and that's why you will see quarter four of this year and quarter two last year, both were lower than quarter one and quarter three |
| In '23, Developed Markets declined by 1% |
| Scott Smith So I think, first of all, from my perspective, the most difficult thing in this business is to find impactful assets that you can develop to become blockbusters that are patented with long-term revenue streams |
| This segment is expected to decline by 8% in 2024 |
| With these dynamics in mind, we have modeled a 2% year-over-year decline for 2024 |
| I am pleased to say that as we begin 2024, I could not be more excited about the future ahead |
| During the last earnings call, we noted that adjusted gross margin would moderate in Q4 due to the timing of segment and product mix |
| In the revenue guidance walk, the 2023 adjusted number of $15.2 billion excludes the result of divestiture that closed in 2023, and includes anticipated foreign exchange headwinds |
| The other thing to keep in mind, Glen, is if you're looking at cash flow on a quarter-to-quarter basis, quarter two and quarter four tend to be lower for us because of our semi-annual interest payments that we have |
| In terms of gross margin, you will expect a little bit of a moderation in the second half |
| And in general, free cash flow tend to be lower in quarter two and quarter four due to timing of semiannual interest payments |
| That's what's hard |
| I had two questions |
| Again, we will see a little bit more momentum behind that |
Please consider a small donation if you think this website provides you with relevant information